Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04739800
Title Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

ovarian cancer

fallopian tube cancer

peritoneum cancer

Therapies

Paclitaxel + Pegylated liposomal doxorubicin + Topotecan

Cediranib + Durvalumab

Cediranib + Olaparib

Cediranib + Durvalumab + Olaparib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.